Developing a pill to treat sickle cell disease
- PMID: 38963861
- DOI: 10.1126/science.adq3757
Developing a pill to treat sickle cell disease
Abstract
A newly identified epigenetic modifier increases fetal hemoglobin in preclinical studies.
Comment on
-
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.Science. 2024 Jul 5;385(6704):91-99. doi: 10.1126/science.adk6129. Epub 2024 Jul 4. Science. 2024. PMID: 38963839
Similar articles
-
Recent insights on the medicinal chemistry of sickle cell disease.Curr Med Chem. 2011;18(15):2339-58. doi: 10.2174/092986711795656117. Curr Med Chem. 2011. PMID: 21517749 Review.
-
Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease.EBioMedicine. 2017 Oct;24:26-27. doi: 10.1016/j.ebiom.2017.09.001. Epub 2017 Sep 5. EBioMedicine. 2017. PMID: 28890145 Free PMC article. No abstract available.
-
Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease.Eur J Haematol. 2024 Sep;113(3):264-272. doi: 10.1111/ejh.14247. Epub 2024 Jun 3. Eur J Haematol. 2024. PMID: 38831675 Review.
-
Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia.Pharmacogenomics. 2022 May;23(7):393-396. doi: 10.2217/pgs-2022-0050. Epub 2022 May 12. Pharmacogenomics. 2022. PMID: 35546339 No abstract available.
-
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.Science. 2024 Jul 5;385(6704):91-99. doi: 10.1126/science.adk6129. Epub 2024 Jul 4. Science. 2024. PMID: 38963839
Cited by
-
Sickle cell anaemia therapy in 2025.Br J Haematol. 2025 Mar;206(3):842-845. doi: 10.1111/bjh.19933. Epub 2024 Dec 22. Br J Haematol. 2025. PMID: 39710962 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical